论文部分内容阅读
目的:探析补血养心抗癌汤联合CAF方案化疗对乳腺癌患者外周血癌胚抗原、血清糖蛋白抗原153影响,以及改善化疗药物所致心脏毒性的研究。方法:应用随机平行对照方法,将108例住院患者按随机数字表法,随机分为两组。对照组54例应用CAF方案化疗,治疗组54例患者应用补血养心汤100 m L,日3次口服;化疗用法、用量同对照组,治疗21 d为1周期。行6周期化疗后观察中医症状改善情况、卡式评分、肿瘤标志物癌胚抗原(CEA)、血清糖蛋白抗原153(CA153)水平,心电图改善,血清肌钙蛋白(c Tn T)、肌酸激酶(CK)及乳酸脱氢酶(LDH)含量的变化,骨髓抑制情况。结果:治疗组第4、第6周期症状评分明显降低,与治疗前比较差异均有统计学意义(P<0.01),对照组第4、6周期症状评分升高明显,与治疗前及治疗组同期相比差异均有统计学意义(P<0.01);治疗后,治疗组改善率为55.56%,对照组改善率为35.18%。两组患者生活质量改善率比较有显著性差异(P<0.05);治疗后两组CEA、CA153与治疗前相比均显著降低(P<0.01),且治疗组降低程度优于对照组(P<0.01);治疗组治疗后异常心电图发生率7.41%低于对照组29.62%,差异有统计学意义(P<0.01),治疗后治疗组c Tn T、CK及LDH含量较治疗前均降低(P<0.01),且低于对照组(P<0.01);治疗后,两组患者血红蛋白、白细胞及血小板计数与治疗前相比均降低(P<0.01),且治疗组降低幅度低于对照组(P<0.01)。结论:补血养心汤联合化疗能改善患者化疗期间出现的临床症状,提高生活质量,减轻心脏毒性,抑制病情进展,临床疗效可靠。
Objective: To investigate the influence of the prescription of Xuexue Yangxin Kang Cancer Decoction combined with CAF regimen on the peripheral blood carcinoembryonic antigen, serum glycoprotein antigen 153 in patients with breast cancer and to improve the cardiotoxicity induced by chemotherapeutics. Methods: Using randomized parallel control method, 108 inpatients were randomly divided into two groups according to the random number table method. In the control group, 54 cases were treated with CAF regimen. In the treatment group, 54 cases were treated with Buxue Yangxin Decoction 100 ml once daily for 3 times. The dosage of chemotherapy was the same as that of the control group. The treatment for 21 days was 1 cycle. After 6 cycles of chemotherapy, we observed the improvement of TCM symptoms, card score, carcinoembryonic antigen (CEA), serum CA153, electrocardiogram, cTn T, creatine Kinase (CK) and lactate dehydrogenase (LDH) content changes, bone marrow suppression. Results: The symptom scores in the 4th and 6th cycles of the treatment group were significantly lower than those before treatment (P <0.01), and the scores of symptoms in the 4th and 6th cycles of the control group increased significantly. Compared with those before treatment and the treatment group Compared with the same period, the differences were statistically significant (P <0.01). After treatment, the improvement rate of the treatment group was 55.56% and that of the control group was 35.18%. There was significant difference in quality of life between the two groups (P <0.05). After treatment, the levels of CEA and CA153 in both groups were significantly lower than those before treatment (P <0.01), and the reduction in treatment group was better than that in control group <0.01). The incidence of abnormal electrocardiogram in the treatment group was 7.41% lower than that in the control group (29.62%), the difference was statistically significant (P <0.01). After treatment, the levels of cTn T, CK and LDH in treatment group were lower than those before treatment (P <0.01), and lower than the control group (P <0.01). After treatment, the hemoglobin, white blood cell count and platelet count of the two groups were lower than those before treatment (P <0.01), and the reduction of the treatment group was lower than that of the control group (P <0.01). Conclusion: The combination therapy of Xuexue Yangxin Decoction and chemotherapy can improve the clinical symptoms, improve the quality of life, reduce the cardiotoxicity and inhibit the progression of the disease in patients during chemotherapy, and the clinical curative effect is reliable.